Last reviewed · How we verify
Stiripentol Oral Capsule
Stiripentol is an antiepileptic drug that works by enhancing the inhibitory effects of GABA.
Stiripentol is an antiepileptic drug that works by enhancing the inhibitory effects of GABA. Used for Seizure control in Dravet syndrome.
At a glance
| Generic name | Stiripentol Oral Capsule |
|---|---|
| Sponsor | Biocodex |
| Drug class | GABA_A receptor modulator |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It does this by increasing the activity of GABA_A receptors, which are responsible for the inhibitory effects of the neurotransmitter GABA. This results in a decrease in neuronal excitability and a reduction in the frequency and severity of seizures.
Approved indications
- Seizure control in Dravet syndrome
Common side effects
- Somnolence
- Dizziness
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) (PHASE1)
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stiripentol Oral Capsule CI brief — competitive landscape report
- Stiripentol Oral Capsule updates RSS · CI watch RSS
- Biocodex portfolio CI